GILD241220C100000
- 0.01
- -0.03-75.00%
Gilead Sciences Newsroom
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Gilead Gets FDA Breakthrough Therapy Status for Trodelvy
Express News | U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (Sacituzumab Govitecan-Hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets
Express News | Gilead Sciences Inc - Transaction Expected to Reduce Gilead's 2024 EPS by $0.01
Express News | Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead Sciences' Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
Gilead (GILD) Upgraded to Buy: Here's Why
Another Week, Another Index Record | Lkive Stock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
The former global development head of Sanofi (SNY.US) has joined Gilead (GILD.US).
Before joining Gilead (GILD.US), Dr. Dietmar Berger served as CMO and Global Development Head at Sanofi (SNY.US).
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
Weekly Buzz: Tech stocks hit high scores on ominous day
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Gilead Gets Key European Backing for Liver-Disease Treatment